ClinicalTrials.gg
CompletedNCT06944717Updated Jul 27, 2026

A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old

A Phase 1 interventional study of VXA-G1.1-NN and VXA-G2.4-NS in Norovirus Infections, sponsored by Vaxart. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Vaxart · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Caliciviridae Infections with a site in United States — none open to participants now, none under way, none of them phase 3. Caliciviridae Infections · United States.

Enrollment
6th of 11
60 · median 60
Started
2025
the only one that year
Phase 1
6 of 11
none open now
Registered
11th of 11
by date
Lead sponsor
7 of 11
Vaxart

Among the 11 studies in Caliciviridae Infections with a site in United States, this one is the 6th largest by enrollment, is the only one that started in 2025, is one of 6 in phase 1, and was the 11th registered.

Caliciviridae Infections

20 studies on the registry are indexed under Caliciviridae Infections; 2 are open to participants now.

Browse Caliciviridae Infections studies →

Open to participants now

None of the 11 studies in Caliciviridae Infections with a site in United States is open now. The open studies under Caliciviridae Infections, anywhere →

Who these studies take

Of the 2 Caliciviridae Infections studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Caliciviridae Infections with a site in United States as a file.
02

Study summary

The primary objective of this study is to determine the safety and immunogenicity of low and high dose regimens of a next generation norovirus bivalent G1.1 and G2.4 vaccine candidate in healthy participants.

03

Conditions studied

  • Norovirus Infections

Keywords

  • Norovirus
  • Healthy participants
  • VXA-G1.1-NN
  • VXA-G2.4-NS
  • VXA-G2.4-NS-T
  • VXA-G1.1-NN-T
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 and ≤ 80 years old at the time of signing the Form (ICF).
  2. In stable and good general health and without significant medical illness (based on review of medical history, physical examination, current health status, and vital signs at Screening) as determined by the Investigator, with Screening lab values within normal limits or abnormalities assessed as not .
  3. (BMI) > 17.0 and \< 35.0 kg/m\^2 at Screening.
  4. Available for all planned visits and tele-health appointments, and willing to complete all Protocol-defined procedures and assessments (including ability and willingness to swallow multiple small enteric-coated tablets per study dose).
  5. Male or female participants.

    1. Female participants must not be breastfeeding and must provide a negative pregnancy test at Screening and pre-dose on Day 0.
    2. Female participants must fulfill at least one of the following criteria:

      • At least 1 year (defined as amenorrhea for ≥ 12 consecutive months prior to Screening without alternative medical cause) or surgically sterile (hysterectomy, bilateral salpingectomy, bilateral oophorectomy, bilateral tubal occlusion/ligation).
      • Female participants of must be willing to use a highly effective form of for 30 days prior to study drug administration and until 60 days after study drug administration. Acceptable forms are oral, implantable, intrauterine, transdermal, intravaginal, injectable, double barrier or abstinence (participants using diaphragms must also use condoms). The Investigator must approve the form of contraception. Female participants must also refrain from egg donation for the 1 month prior to dosing through 60 days post-vaccination.
    3. Male participants must fulfill one of the following criteria:

      • Male participants must agree to refrain from donating sperm and practice abstinence from all intercourse or use an effective method of birth control which includes condom use from study drug administration to 90 days post-dose.
      • At least 1 year post-vasectomy and have confirmed that they have obtained documentation of the absence of sperm in the ejaculate.
  6. Capable of understanding and giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in the Protocol.

Exclusion criteria

Exclusion Criteria

  1. Presence of significant uncontrolled medical or psychiatric illness (acute or chronic) including institution of new medical/surgical treatment or significant dose alteration for uncontrolled symptoms or drug toxicity within 3 months prior to Screening and reconfirmed at baseline.
  2. Cancer, or treatment for cancer or any procedure or preventive medication for cancer or to prevent recurrence, within past 3 years (excluding fully treated and resolved basal cell carcinoma or squamous cell carcinoma).
  3. Presence of or medical condition possibly associated with impaired immune responsiveness, including diabetes mellitus- type 1 and 2, asplenia, and functional asplenia.
  4. History of irritable bowel disease or other inflammatory digestive or gastrointestinal condition that could affect the distribution/safety evaluation of an orally administered vaccine targeting the mucosa of the small intestine. Such conditions may include but are not limited to:

    1. Any history of:

      • Gastrointestinal
      • Masabsorption
      • Pancreato-biliary disorders
      • Inflammatory bowel disease
      • Irritable bowel disease
      • Hiatal hernia
      • Surgical resection
    2. History of diagnosis or treatment in past 5 years of:

      • Osophageal or gastric motility disorder
      • Gastro esophageal reflux disorder if any of the following is met:

        • History of severe or uncontrolled gastroesophageal reflux disease (GERD) at any point during this period.
        • History of complicated GERD at any point during this period.
        • Was on treatment for 12 continuous weeks at any point during this period.
        • Has been with chronic or frequent GERD symptoms (e.g., more than twice per week) in the past year.
      • Peptic ulcer if any of the following is met:

        • History of severe or uncontrolled peptic ulcer at any point during this period.
        • History of complicated peptic ulcer at any point during this period.
        • Was on treatment for 12 continuous weeks at any point during this period.
        • Has been with chronic or frequent peptic ulcer symptoms (e.g., more than twice per week) in the past year.
      • Cholecystectomy if any of the following is met:

        • Procedure was performed within 1 year of dosing.
        • The participants has ongoing / unresolved post-cholecystectomy digestive symptoms within 30 days prior to dosing.
  5. History of any form of angioedema.
  6. History of serious reactions to vaccination such as anaphylaxis, respiratory problems, hives, or abdominal pain.
  7. Known to blood draws (e.g., bleeding diathesis, acquired coagulopathy, significant bleeding, or bruising) or to oral route of administration (unable to swallow tablets).
  8. Has an acute disease within 72 hours prior to study drug administration, defined as the presence of a moderate or severe illness (as determined by the Investigator through medical history and physical exam), including the following (Note: Assessment may be repeated once during Screening Period):

    1. An acute illness that is nearly resolved, with only minor residual symptoms remaining, is allowable if, in the opinion of the site investigator, the residual symptoms will not interfere with the ability of study staff to assess safety parameters as required by the Protocol.
    2. Presence of a fever ≥ 38.0°C (100.4°F) measured orally at baseline on Day 1 prior to dosing.
    3. Receipt of antipyretic/analgesic medications within 24 hours prior to vaccine administration.
  9. Any significant hospitalization within the last year which in the opinion of the Investigator or Sponsor could interfere with study participation.
  10. Any of the following personal and/or family history or conditions that may lead to higher risk of clotting events and/or thrombocytopenia:

    1. Familial coagulopathy or hypercoagulability or personal history of bleeding disorder or thrombosis/embolus.
    2. History of heparin-related thrombotic events, and/or receiving heparin treatments.
    3. History of or inflammatory disease such as autoimmune thyroiditis, vitiligo, rheumatoid arthritis.
    4. Presence of any of the following conditions known to increase risk of thrombosis within 6 months prior to Screening:

      • Recent surgery other than removal/ of cutaneous lesions.
      • Immobility (confined to bed or wheelchair for 3 or more successive days).
      • Head trauma with loss of consciousness or documented brain injury.
      • Receipt of anticoagulants for prophylaxis of thrombosis.
      • Recent infection, including hospitalization for Coronavirus Disease 19 (COVID-19) related illness.
  11. Any other condition that in the clinical judgement of the investigator would jeopardize the safety or rights of a participant taking the study drug, would render the participant unable to comply within the Protocol or would interfere with the evaluation of the study endpoints diagnostic assessments including a history of drug, alcohol, or chemical abuse within 1 year of Screening.
  12. Positive (HIV), surface antigen (HBsAg), or virus (HCV) tests at the Screening visit.
  13. History of gastrointestinal bleeding including hematochezia (blood in stool) or melena (black stool) of unknown etiology or that has not been evaluated.
  14. Positive urine drug screen (UDS) for drugs of abuse at Screening (positive test for marijuana is not exclusionary; however concurrent use of marijuana during the Active Study Period through Day 28 is prohibited). Positive UDS at Screening due to prescribed stimulants will be reviewed on a case by case basis.
  15. Positive breath or urine alcohol test at baseline (prior to dosing).
  16. Receipt of a licensed vaccine (including any COVID-19 vaccines under Emergency Use Authorization [EUA]) within 14 days prior to study drug administration or planned administration during the Active Study Period (Day 28).
  17. Use of antibiotics, proton pump inhibitors, H2 blockers or antacids within 7 days prior to study drug administration or planned use during the active study period (up to Day 28).
  18. Use of drugs known to affect gastrointestinal motility including glucagon-like peptide 1 receptor agonists including tirzepatide (Mounjaro) and semaglutide (Wegovy, Ozempic) within 30 days prior to drug administration or planned use through Day 7. Okay to restart after Day 7 if with full resolution of solicited symptoms of reactogenicity.
  19. Use of medications known to affect the immune function (e.g., including but not limited to (systemic, intranasal, inhaled, or intra-articular), leukotriene modifiers, and Janus kinase inhibitors) within 14 days before study drug administration or planned use during the Active Study Period (up to Day 28).

    a. Exception to the timeframe: allergen immunotherapy (AIT) will be allowed only if the participant is stable in the maintenance phase of AIT. Maintenance AIT should not be dosed for at least 7 days before and 7 days after study vaccine dosing, and the Principal Investigator must document the treating allergist's approval.

  20. Daily use of nonsteroidal anti-inflammatory drugs within 7 days prior to study drug administration or planned use during the active study period (up to Day 28). Low daily doses of acetylsalicylic acid ≤ 100 mg for cardio-protection is not exclusionary.
  21. Administration of any vaccine, drug or device within 8 weeks preceding study drug administration, or planned use within the duration of the study.
  22. Previous participation in a Vaxart Clinical Trial or other norovirus vaccine trial unless confirmed receipt of placebo.
  23. Donation or use of blood or blood products within 30 days prior to study drug administration or planned donation during the active study period (up to Day 28).
  24. History of or allergic reaction to any component of the investigational vaccine, including but not limited to, fish gelatin allergy.
  25. Study team member or first-degree relative of any study team member (inclusive of Sponsor and site personnel involved in the study).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Bivalent Low Dose Next Generation Vaccine

    Healthy participants will receive Norovirus GI.1 Norwalk VP1 Vaccine, Modified Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant (VXA-G1.1-NN-T) (1x10\^10 infectious units (IU)) and Norovirus GII.4 Sydney VP1 Vaccine, Modified Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant (VXA-G2.4-NS-T) (1x10\^10 IU) orally.

    Biological: VXA G1.1 NN-T · Biological: VXA G2.4 NS-T

  • Experimental
    Bivalent High Dose Legacy Vaccine

    Healthy participants will receive Norovirus GI.1 Norwalk Vaccine Protein 1 (VP1) Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with double-stranded ribonucleic acid (dsRNA) Adjuvant (VXA-G1.1-NN) (1x10\^11 IU) and Norovirus GII.4 Sydney VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant (VXA-G2.4-NS) (1x10\^11 IU) orally.

    Biological: VXA-G1.1-NN · Biological: VXA-G2.4-NS

  • Experimental
    Bivalent High Dose Next Generation Vaccine

    Healthy participants will receive VXA-G1.1-NN-T (1x10\^11 IU) and VXA-G2.4-NS-T (1x10\^11 IU) orally. A sentinel group will be enrolled, if there is positive recommendation from the safety monitoring committee, enrollment will continue in this arm.

    Biological: VXA G1.1 NN-T · Biological: VXA G2.4 NS-T

Interventions

  • BiologicalVXA-G1.1-NN

    Legacy vaccine, administered orally.

  • BiologicalVXA-G2.4-NS

    Legacy vaccine, administered orally.

  • BiologicalVXA G1.1 NN-T

    Next generation vaccine, administered orally.

  • BiologicalVXA G2.4 NS-T

    Next generation vaccine, administered orally.

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Solicited Symptoms of Reactogenicity (Gastrointestinal and Systemic) for 1 Week Following Study Intervention Dose

    Time frame: 7 days

  2. Duration of Solicited Symptoms of Reactogenicity (Gastrointestinal and Systemic) for 1 Week Following Study Intervention Dose

    Time frame: Approximately 1 year

  3. Severity of Solicited Symptoms of Reactogenicity (Gastrointestinal and Systemic) for 1 Week Following Study Intervention Dose

    Time frame: 7 days

  4. Number of Participants Experiencing Unsolicited Adverse Events (AE) for 28 Days Following the Study Intervention Dose

    Time frame: 28 days

  5. Number of Participants Experiencing Unsolicited New Onset of Chronic Illness (NOCI) for 28 Days Following the Study Intervention Dose

    Time frame: 28 days

  6. Duration of Unsolicited AEs for 28 Days Following the Study Intervention Dose

    Time frame: Approximately 1 year

  7. Duration of Unsolicited NOCIs for 28 Days Following the Study Intervention Dose

    Time frame: Approximately 1 year

  8. Severity of Unsolicited AEs for 28 Days Following the Study Intervention Dose

    Time frame: 28 days

  9. Severity of Unsolicited NOCIs for 28 Days Following the Study Intervention Dose

    Time frame: 28 days

  10. Geometric Mean Titer (GMT) at Day 0 of Serum Functional Antibody Against GI.1 Measured by Norovirus Blocking Antibody Assay (NBAA)

    Time frame: Day 0

  11. GMT at Day 28 of Serum Functional Antibody Against GI.1 Measured by NBAA

    Time frame: Day 28

  12. GMT at Day 0 of Serum Functional Antibody Against GII.4 Measured by NBAA

    Time frame: Day 0

  13. GMT at Day 28 of Serum Functional Antibody Against GII.4 Measured by NBAA

    Time frame: Day 28

  14. Geometric Mean Fold Rise (GMFR) from Day 0 to Day 28 of Serum Functional Antibody Against GI.1 Measured by NBAA

    Time frame: From Day 0 to Day 28

  15. GMFR from Day 0 to Day 28 of Serum Functional Antibody Against GII.4 Measured by NBAA

    Time frame: From Day 0 to Day 28

07

Study locations

1 site
  • Johnson County Clin Trials - JCCT
    Lenexa, Kansas 66219, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Apr 2026, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2025
First posted
Apr 25, 2025
StartActual
Mar 3, 2025
Primary completionActual
Apr 14, 2026
CompletionActual
Apr 14, 2026
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06944717
Lead sponsor
Vaxart
Responsible party
Sponsor
First posted
Apr 25, 2025
Start date
Mar 3, 2025
Primary completion
Apr 14, 2026
Completion
Apr 14, 2026
Last update
Jul 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VXA-G1.1-NN

Start the discussion